UNSPSC 51284029: Doxycycline hydrochloride hemiethanolate hemihydrate

This classification denotes a tetracycline antibiotic with the molecular formula 2C22H24N2O8.C2H6O.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19XTS3T51U, chemically known as 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate, but more generally known as doxycycline hydrochloride hemiethanolate hemihydrate, which bears US NIH Compound Identifier 5282244.

UNSPSC 51284029 Doxycycline hydrochloride hemiethanolate hemihydrate is a Commodity code that covers pharmaceutical-grade antibiotic products supplied through state and local health procurement channels. State and local governments acquire this substance primarily through piggyback purchasing vehicles and cooperative frameworks tied to public health initiatives, including emergency preparedness, communicable disease treatment, and community health programs. The work involves warehousing, packaging, and distribution of pharmaceutical inventory to public health agencies and community health facilities, with vendors managing compliance around product expiration timelines, storage specifications, and delivery logistics.

Recent activity shows Illinois Department of Public Health as a buyer of this product class, procuring doxycycline hyclate 100mg tablets through the MMCAP Infuse consortium. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract to Chartwell Rx LLC on August 28, 2026 (Bid Number 26-482DPH-PREPD-B-53392) valued at $2,999,999.11 over three years for doxycycline hyclate 100mg in 20-count packages and ciprofloxacin hydrochloride 500mg tablets, with an initial 12-month term and two renewal options. The procurement used an Invitation for Bid process with Chartwell Rx LLC selected as the lowest priced responsive and responsible bidder. Geographically, Illinois and Florida have recent documented activity; the source shows no additional state-level procurement under this code in the recent-opportunities block, suggesting concentrated rather than dispersed state and local demand for this specific pharmaceutical product.